Last reviewed 2026-04-20 · How we verify

LDAC (ldac)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Neutropenia
• Thrombocytopenia
• Anaemia
• Diarrhoea
• Constipation
• Nausea
• Pyrexia
• NAUSEA
• Fatigue
• DIARRHOEA
• Hypokalaemia
• Asthenia

Key clinical trials

• Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (PHASE2)
• Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia (PHASE1)
• Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia (PHASE1, PHASE2)
• Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia (PHASE2)
• Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
• A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy (PHASE3)
• FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies (PHASE1)
• An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.